Capabilities

Capabilities

Osler Menu

Comprehensive test menu

Consolidating multiple existing systems onto a single instrument

Speedometer (1)

High performance

Quantitative, accurate, sensitive, and multiplexed

Planet

For anyone, anywhere, at any time

Portable, low-cost, quick, and easy to use

Find out more

Applications

The Osler Origin will transform global healthcare by offering a wide portfolio of tests across all healthcare settings.

You will find us in the Emergency Department, Doctor’s Office, Retail Pharmacy and more...

Technology

Tech Circuit

Powered by Osler's lab-in-your-hand technology, with proprietary Osler HemaTap sample addition, microfluidic sample preparation, and electrochemical biosensing

Tech Badge

Based on decades of Oxford University research, followed by years of Osler industrialisation, that made the promise of the Osler Origin product a reality

Tech Doc

Protected by a comprehensive intellectual property portfolio

Executives

Connor Campbell

Co-Founder and CEO

Connor is the Co-Founder and CEO of Osler.

Previous roles include Principal at Oxford Science Enterprises (Science Business Builder and preferred investment partner of the University of Oxford) and Consultant for McKinsey & Company, where his work included supporting the Government of Sierra Leone in the wake of the Ebola health crisis.

Connor received a degree in Medical Sciences from the University of Oxford.

https://uk.linkedin.com/in/connor-campbell-47351aa0

Tom Parenteau

Chief Commercial Officer

Tom is responsible for commercial strategy development and implementation, and overseeing product, marketing, business development, sales, and more.

Previous roles, in his 25+ year career, include:

  • Global Commercial Director, Point of Care at ThermoFisher – where he established and led the distribution and sales of point of care platforms to over 70 countries worldwide
  • Senior Director of Global Product Marketing and Scientific Affairs at Alere, where he oversaw the Biosite Triage, Cholestech LDX and HemoSense INRatio portfolios
  • Director of Global Marketing for Diagnostics at Novartis, where he focused on molecular infectious disease screening of the world’s blood supply
  • Global Director of OEM & Diagnostics at ThermoFisher (Invitrogen), where he oversaw the selling and licensing of a wide product portfolio, to all major global diagnostic companies
  • Several leadership roles at Bio-Rad Laboratories involving sales, marketing and business development

Tom received a degree in Biology and Chemistry from the University of Kentucky, and an MBA from Loyola University Chicago.

https://uk.linkedin.com/in/tom-parenteau-4751462

David Edington

Chief Technology Officer

As Osler's founding CTO, David has overall responsibility for research & development and technology strategy at Osler. 

Previous roles include VP, R&D at DNA Electronics (the inventors of semiconductor-based DNA sequencing) and technical leadership of a range of diagnostic and drug delivery device development programmes at PA Consulting Group, including spin-outs of venture companies in the point of care diagnostics field.

David holds a PhD in Physics from the University of Edinburgh, UK which involved the development of optical instruments and spectroscopic techniques for the analysis of molecular liquids.

https://uk.linkedin.com/in/david-edington-5a96802

Paul Dixon

Chief Financial Officer

Paul is responsible for all of Osler’s finance, operations, and business support functions as well as assisting with investor relations. 

Previous roles include Finance Director positions in M&A, Financial Services, and Sales and Lettings at Countrywide plc (a former FTSE 250 real estate group) and as a Senior Manager at KPMG, where he worked internationally in the fields of audit, financial reporting and governance.

Paul is a Fellow Chartered Accountant of the ICAEW and received a Degree in Chemistry from the University of Oxford.

https://uk.linkedin.com/in/pmdixon

Board of Directors

Chris Smith

Chairman

Chris Smith is the CEO of Ortho Clinical Diagnostics (‘Ortho’), a leading global diagnostic company. In December 2021, Quidel Corporation announced that it would acquire Ortho for around $6 billion. 

Prior to joining Ortho, Chris was CEO of Cochlear, a global medical device company headquartered in Australia. Under his leadership, Cochlear reached annual sales in excess of AU$1 billion while the market cap of the company more than doubled. Prior to taking over as CEO, Chris served as the president of Cochlear Americas, more than quadrupling revenue during his tenure.

Prior to Cochlear, Chris held several senior executive roles, including CEO in residence for Warburg Pincus and global group president of Gyrus Group Plc., a surgical products company. In addition, early in his career he held roles in Abbott, Cardinal, Prism and KCI. Chris has also served as a senior external advisor for McKinsey & Co., and EQT Partners. Chris holds a Bachelor of Science degree from Texas A&M University.

https://www.linkedin.com/in/chris-smith-a8baa441/

David Berry

Non-Executive Director

David Berry is Founder and CEO of Valo Health, and since 2005 has worked at Flagship Pioneering, where he is a General Partner, focused on conceiving, creating, resourcing, and launching groundbreaking companies. David has co-founded more than 20 companies across life sciences and sustainability.

David has been broadly recognized as a world-leading innovator: elected as a Young Global Leader by the World Economic Forum, named as Innovator of the Year by MIT Technology Review from amongst its annual TR35 list, and selected as one of 12 Innovators Reshaping Reality by the U.S. State Department, alongside pioneers such as Tim Berners-Lee. He holds over 200 patents and patent applications, and he and his companies have been awarded with more than 150 additional awards and honours. David also serves on the United Nations Sustainable Development Solutions Network (UN SDSN), where he was a Founding Leadership Council Member.

David received his M.D. from Harvard Medical School and his Ph.D. from MIT in biological engineering, through the Health Sciences and Technology program, completing the fastest dual degree in the modern history of the program.

https://www.linkedin.com/in/davidberrymdphd/

Jörg Debatin

Non-Executive Director

Jorg began his professional career in Diagnostic Radiology, working at Duke, Stanford, Zurich and Essen, where he was appointed Professor of Diagnostic Radiology in 1999. He subsequently served as Medical Director & CEO of the University Medical Center, Hamburg-Eppendorf. In 2011 he moved to industry as CEO of Amedes AG, a European diagnostics services provider, and from 2014 to 2018 as Vice President and Chief Technology Officer for GE Healthcare, where he oversaw the technology and product portfolio strategy for GE’s $19Bn healthcare businesses, including advising GE Ventures on its healthcare portfolio investments. Most recently, he led the health innovation hub (hih), an interdisciplinary team of 15 experts, assembled to advance the digital agenda within the German Healthcare System, working closely with the Federal Ministry of Health.

Jorg received his Medical Degree from the University of Heidelberg and holds an MBA from Hochschule St.Gallen (HSG) in Switzerland.

https://www.linkedin.com/in/prof-dr-med-j%C3%B6rg-felix-debatin-mba-05b93a164/

Amber Salzman

Non-Executive Director

Amber is the CEO of a stealth gene regulation company and sits on the Board of Aviado Bio, a gene therapy company, and Biotechnology Innovation Organization, an association that represents the biotechnology industry.

Amber began her career at GlaxoSmithKline where she was responsible for clinical trials globally with 30,000+ active patients, directing a budget of $1.25B and 1,600 employees worldwide. She then served as CEO of Cardiokine, until its sale to Cornerstone Therapeutics. After Cardiokine, Amber launched Annapurna, a gene therapy company that merged with Avalanche (NASDAQ:AAVL) to create Adverum Biotechnologies (NASDAQ:ADVM). After serving as CEO for Adverum, Amber returned to the east coast to lead Ohana Biosciences, a Flagship Pioneering company, establishing the industry’s first sperm product platform. Concurrent with industry positions, Amber leads a non-profit medical research foundation focused on accelerating the development of therapies for adrenoleukodystrophy (ALD).

Amber received a PhD in Mathematics from Bryn Mawr College in Pennsylvania, and a degree in Computer Science from Temple University in Philadelphia.

https://www.linkedin.com/in/ambersalzman

Peter George

Non-Executive Director

Peter is a strategic advisor to Ergomed (a global full-service CRO), and Gresham House (a specialist alternative asset manager), in addition to serving as Founder & Chairman of Enigma Holdings (an investment company that specialises in health, wellbeing, sport, learning, community and social housing), Chairman of Benchmark Holdings (a provider of technical genetic services to the food production industry), and Chairman of Oxford Quantum Circuits.

Previously, Peter held executive positions at various pharmaceutical and life sciences companies, and founded Clinigen Group plc, a global specialty pharmaceuticals and pharma services business. Clinigen was founded in 2010, floated in 2012, and by 2016 had a c.£1bn+ market cap, being one of the most successful floats on the AIM stock market.

Peter received a MSc in Biochemistry and in Immunology from the University of Nottingham, and an MBA from Northwestern University - Kellogg School of Management.

https://uk.linkedin.com/in/peter-george-0986601

Erich Reinhardt

Non-Executive Director

Erich was President & CEO of Siemens Healthcare, a role he held from 1994 to 2008 where he was responsible for growing the business to make Siemens the #1 global diagnostics company. Erich was also a member of the executive board of Siemens AG. From 2008 to 2021, Erich was Chairman of Medical Valley EMN, the leading MedTech cluster in Germany, which focused on providing effective and efficient health solutions. In addition, he has experience in several private equity projects with EQT, including serving as Chairman of Gambro and Chairman of BSN.

Erich received a Master’s degree and a PhD in electrical engineering at the University of Stuttgart in Germany and was later appointed honorary professor.

https://www.linkedin.com/in/erich-r-reinhardt-8747148b/

Andre Crawford-Brunt

Non-Executive Director

Andre is the Founder and General Partner of Braavos Investment Advisors and a Director of Oxford Science Enterprises (Science Business Builder and preferred investment partner of the University of Oxford). Andre is an active individual investor, backing the likes of Jet.com and Kensho Technologies, and more recently top life-science start-ups.

Previously, Andre was the Global Head of Equity Trading at Deutsche Bank and a Director at Sygnia Asset Management.

Andre received a degree in Business Administration and Management from Rhodes University in South Africa.

https://uk.linkedin.com/in/andre-crawford-brunt-7a9a0589

Connor Campbell

CEO and Co-Founder

Connor is the Co-Founder and CEO of Osler.

Previous roles include Principal at Oxford Science Enterprises (Science Business Builder and preferred investment partner of the University of Oxford) and Consultant for McKinsey & Company, where his work included supporting the Government of Sierra Leone in the wake of the Ebola health crisis.

Connor received a degree in Medical Sciences from the University of Oxford.

https://uk.linkedin.com/in/connor-campbell-47351aa0

Paul Dixon

Chief Financial Officer

Paul is responsible for all of Osler’s finance, operations, and business support functions as well as assisting with investor relations. 

Previous roles include Finance Director positions in M&A, Financial Services, and Sales and Lettings at Countrywide plc (a former FTSE 250 real estate group) and as a Senior Manager at KPMG, where he worked internationally in the fields of audit, financial reporting and governance.

Paul is a Fellow Chartered Accountant of the ICAEW and received a Degree in Chemistry from the University of Oxford.

https://uk.linkedin.com/in/pmdixon

Join our team

Join our team
engineer